Melissa J Mcdonnell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5134493/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	3.2	6
2	Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. European Respiratory Journal, 2020, 55, 2000351.	6.7	81
3	Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1133-1145.	5.6	26
4	ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly. ERJ Open Research, 2020, 6, 00341-2019.	2.6	3
5	Current therapies for gastro-oesophageal reflux in the setting of chronic lung disease: state of the art review. ERJ Open Research, 2020, 6, 00190-2019.	2.6	15
6	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. The Lancet Global Health, 2019, 7, e1269-e1279.	6.3	116
7	Bendopnoea in exercise limited patients with COPD. Respiratory Medicine, 2019, 154, 141-143.	2.9	1
8	Research highlights from the 2018 European Respiratory Society International Congress: airway disease. ERJ Open Research, 2019, 5, 00225-2018.	2.6	3
9	The independent contribution of <i>Pseudomonas aeruginosa</i> infection to long-term clinical outcomes in bronchiectasis. European Respiratory Journal, 2018, 51, 1701953.	6.7	150
10	Characterization of the "Frequent Exacerbator Phenotype―in Bronchiectasis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1410-1420.	5.6	215
11	Risk factors for lung disease progression in children with cystic fibrosis. European Respiratory Journal, 2018, 52, 1801492.	6.7	1
12	Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent RiskÂFactor for Mortality in Patients WithÂBronchiectasis. Chest, 2017, 151, 1247-1254.	0.8	81
13	Patterns of Disease in Patients with Middle-Lobe Predominant Bronchiectasis. Respiration, 2017, 93, 406-414.	2.6	10
14	European Respiratory Society guidelines for the management of adult bronchiectasis. European Respiratory Journal, 2017, 50, 1700629.	6.7	788
15	Standardised classification of the aetiology of bronchiectasis using an objective algorithm. European Respiratory Journal, 2017, 50, 1701289.	6.7	63
16	Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation. Journal of Cystic Fibrosis, 2017, 16, 124-131.	0.7	20
17	Characterization of bronchiectasis in the elderly. Respiratory Medicine, 2016, 119, 13-19.	2.9	28
18	Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respiratory Medicine,the, 2016, 4, 969-979.	10.7	210

Melissa J McDonnell

#	Article	IF	CITATIONS
19	The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. Respiratory Medicine, 2016, 112, 51-58.	2.9	27
20	Clinical phenotypes in adult patients with bronchiectasis. European Respiratory Journal, 2016, 47, 1113-1122.	6.7	215
21	Etiology of Non–Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. Annals of the American Thoracic Society, 2015, 12, 1764-1770.	3.2	233
22	A Comprehensive Analysis of the Impact of <i>Pseudomonas aeruginosa</i> Colonisation on Prognosis in Adult Bronchiectasis. Annals of the American Thoracic Society, 2015, 12, 1602-11.	3.2	258
23	ERS International Congress 2021: highlights from the Respiratory Infections Assembly. ERJ Open Research, 0, , 00642-2021.	2.6	0
24	Epithelial Mesenchymal Plasticity as a Potential Common Link between Lung Disease and Increased Risk of Lung Cancer. Annals of the American Thoracic Society, 0, , .	3.2	0